Dr. Robert Haddad shared advances in head and neck cancer, highlighting perioperative pembrolizumab's FDA approval. Unlike past trials, Keynote 689 showed improved event-free survival. Nivo Post-Op also benefited high-risk patients, underscoring multidisciplinary care's role in treatment progress.